Phreesia, Inc. – NYSE:PHR
Founder-led company
Phreesia stock price today
$27.94
+2.17
+8.46%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market open
Closed in about 2 hours
Phreesia stock price monthly change
+19.81%
month
Phreesia stock price quarterly change
+19.81%
quarter
Phreesia stock price yearly change
+11.32%
year
Phreesia key metrics
Market Cap | 1.46B |
Enterprise value | 1.47B |
P/E | -9.3 |
EV/Sales | 5.24 |
EV/EBITDA | -10.60 |
Price/Sales | 5.86 |
Price/Book | 5.72 |
PEG ratio | 0.22 |
EPS | -2.89 |
Revenue | 285.52M |
EBITDA | -125.30M |
Income | -151.46M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | -62.71% |
Oper. margin | -62.85% |
Gross margin | 65.67% |
EBIT margin | -62.85% |
EBITDA margin | -43.89% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freePhreesia stock price history
Phreesia stock forecast
Phreesia financial statements
Average Price Target
$31.75
Potential upside: 13.63%
Analysts Price target
Financials & Ratios estimates
| Oct 2021 | 55.91M | -36.34M | -65% |
|---|---|---|---|
| Jan 2022 | 58.02M | -46.45M | -80.06% |
| Jan 2023 | 76.58M | -38.02M | -49.64% |
| Jan 2024 | 95.00M | -30.64M | -32.26% |
0%
Yield TTM
| Payout ratio | 0% |
|---|
| 2020 | 2.38% |
|---|---|
| 2021 | |
| 2022 | |
| 2023 | |
| 2024 |
| Jul 2022 | 425988000 | 77.52M | 18.2% |
|---|---|---|---|
| Oct 2022 | 397294000 | 76.94M | 19.37% |
| Jan 2023 | 370057000 | 82.23M | 22.22% |
| Jan 2024 | 371085000 | 119.63M | 32.24% |
| Oct 2021 | -24.52M | -14.50M | -425K |
|---|---|---|---|
| Jan 2022 | -37.97M | -40.67M | -7.93M |
| Jan 2023 | -15.89M | -6.59M | -10.01M |
| Jan 2024 | -2.82M | -8.15M | -4.86M |
Phreesia alternative data
| Sep 2023 | 1,576 |
|---|---|
| Oct 2023 | 1,576 |
| Nov 2023 | 1,576 |
| Dec 2023 | 1,576 |
| Jan 2024 | 1,576 |
| Feb 2024 | 1,576 |
| Mar 2024 | 1,438 |
| Apr 2024 | 1,438 |
| May 2024 | 1,438 |
| Jun 2024 | 1,438 |
| Jul 2024 | 1,438 |
Phreesia other data
55.54%
-37.08%
of PHR is owned by hedge funds
129
-48
29.12M
-19.60M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jan 2024 | 0 | 192805 |
| Feb 2024 | 0 | 1288 |
| Mar 2024 | 0 | 30081 |
| Apr 2024 | 0 | 64619 |
| May 2024 | 0 | 286 |
| Jun 2024 | 0 | 248 |
| Jul 2024 | 0 | 15380 |
| Aug 2024 | 0 | 14110 |
| Sep 2024 | 0 | 21452 |
| Oct 2024 | 0 | 13957 |
| Dec 2024 | 0 | 65599 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | ROBERTS EVAN officer: Chief Operating Officer | Common Stock | 25,000 | $24.09 | $602,150 | ||
Sale | VANDUYN AMY BETH officer: SVP, Human Resources | Common Stock | 25,447 | $20.93 | $532,555 | ||
Option | WEINTRAUB MICHAEL director | Common Stock | 15,152 | $2.03 | $30,759 | ||
Sale | WEINTRAUB MICHAEL director | Common Stock | 15,152 | $21.01 | $318,374 | ||
Option | WEINTRAUB MICHAEL director | Stock Options (Right to Buy) | 15,152 | $2.03 | $30,759 | ||
Sale | LINETSKY DAVID officer: SVP, Lif.. | Common Stock | 1,100 | $20.49 | $22,539 | ||
Sale | HUI YVONNE officer: Principal Accounting O.. | Common Stock | 423 | $21.33 | $9,023 | ||
Sale | GANDHI BALAJI officer: Chief Financial Officer | Common Stock | 864 | $21.03 | $18,166 | ||
Sale | HOFFMAN ALLISON C officer: General .. | Common Stock | 1,212 | $21.03 | $25,482 | ||
Sale | INDIG CHAIM director, officer.. | Common Stock | 3,089 | $21.03 | $64,946 |
| Quarter | Transcript |
|---|---|
| Q1 2025 30 May 2024 | Q1 2025 Earnings Call Transcript |
| Q4 2024 14 Mar 2024 | Q4 2024 Earnings Call Transcript |
| Q3 2024 5 Dec 2023 | Q3 2024 Earnings Call Transcript |
| Q2 2024 6 Sep 2023 | Q2 2024 Earnings Call Transcript |
Buy Certara After The FDA Announcement
Phreesia Continues To Stay Positive On The Business Growth
Phreesia: Remain Buy Rated As The Business Pivot Towards Profitable Growth
Phreesia Expects Slower Revenue Growth In Fiscal 2024
Phreesia: Strong Execution Should Continue To Drive Growth
Phreesia: Continuous Strong Execution
Phreesia: Strong Growth Momentum With Expanded TAM
Nutex Health: The Hype Is Over
Phreesia: Healthcare Ecosystem At An Attractive Valuation
-
What's the price of Phreesia stock today?
One share of Phreesia stock can currently be purchased for approximately $27.94.
-
When is Phreesia's next earnings date?
Unfortunately, Phreesia's (PHR) next earnings date is currently unknown.
-
Does Phreesia pay dividends?
No, Phreesia does not pay dividends.
-
How much money does Phreesia make?
Phreesia has a market capitalization of 1.46B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 26.84% to 356.3M US dollars.
-
What is Phreesia's stock symbol?
Phreesia, Inc. is traded on the NYSE under the ticker symbol "PHR".
-
What is Phreesia's primary industry?
Company operates in the Healthcare sector and Medical - Healthcare Information Services industry.
-
How do i buy shares of Phreesia?
Shares of Phreesia can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Phreesia's key executives?
Phreesia's management team includes the following people:
- Mr. Chaim Indig Co-Founder, Chief Executive Officer & Director(age: 46, pay: $905,380)
- Mr. David Linetsky Senior Vice President of Life Sciences(age: 46, pay: $578,460)
- Mr. Evan Roberts Co-Founder & Chief Operating Officer(age: 45, pay: $578,460)
- Ms. Allison C. Hoffman Gen. Counsel & Sec.(age: 54, pay: $267,020)
-
Is Phreesia founder-led company?
Yes, Phreesia is a company led by its founders Mr. Chaim Indig and Mr. Evan Roberts.
-
How many employees does Phreesia have?
As Jul 2024, Phreesia employs 1,438 workers.
-
When Phreesia went public?
Phreesia, Inc. is publicly traded company for more then 6 years since IPO on 18 Jul 2019.
-
What is Phreesia's official website?
The official website for Phreesia is phreesia.com.
-
Where are Phreesia's headquarters?
Phreesia is headquartered at 434 Fayetteville Street, Raleigh, NC.
-
How can i contact Phreesia?
Phreesia's mailing address is 434 Fayetteville Street, Raleigh, NC and company can be reached via phone at +888 6547473.
-
What is Phreesia stock forecast & price target?
Based on 4 Wall Street analysts` predicted price targets for Phreesia in the last 12 months, the avarage price target is $31.75. The average price target represents a 13.63% change from the last price of $27.94.
Phreesia company profile:
Phreesia, Inc.
phreesia.comExchange:
NYSE
Full time employees:
1,438
Industry:
Medical - Healthcare Information Services
Sector:
Healthcare
Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. Its Phreesia Platform offers a suite of solutions to manage the patient intake process, as well as an integrated payments solution for processing of patient payments. The company deploys its platform in a range of modalities, such as Phreesia Mobile, a patients' mobile device; Phreesia Dashboard, a web-based dashboard for healthcare services clients; PhreesiaPads, which are self-service intake tablets; and Arrivals Kiosks that are on-site kiosks. Its Phreesia Platform also provides a registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, and cost estimation tools; access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking; and life sciences solution to deliver targeted and clinically relevant marketing content to patients. In addition, the company's Phreesia Platform offers clinical support solution, which collects clinical intake and patient reported outcome (PRO) data for approximately 25 specialties, as well as enables healthcare services clients to communicate with their patients through surveys, announcements, text and email messaging, and health campaigns; and COVID-19 support modules for managing COVID-19 vaccine delivery and identify vaccine-hesitant patients, screening for self-reported COVID-19 risk factors, enabling contactless check-in during in-person visits, and collecting intake information during telehealth visits. It serves patients; single-specialty practices, multi-specialty groups, and health systems; and pharmaceutical, medical device, and biotechnology companies. The company was incorporated in 2005 and is headquartered in Raleigh, North Carolina.
434 Fayetteville Street
Raleigh, NC 27601
Raleigh, NC 27601
CIK: 0001412408
ISIN: US71944F1066
CUSIP: 71944F106
